Header Logo

Connection

NICOLA HANANIA to Administration, Inhalation

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Administration, Inhalation.
NICOLA HANANIA
Connection Strength
3.719
Administration, Inhalation
  1. POINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? Yes. Chest. 2024 Jul; 166(1):12-17.
    View in: PubMed
    Score: 0.225
  2. Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
    View in: PubMed
    Score: 0.215
  3. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. Int J Chron Obstruct Pulmon Dis. 2023; 18:407-418.
    View in: PubMed
    Score: 0.206
  4. Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. Mayo Clin Proc. 2023 02; 98(2):301-315.
    View in: PubMed
    Score: 0.204
  5. Revisiting Mild Asthma: Current Knowledge and Future Needs. Chest. 2022 01; 161(1):26-39.
    View in: PubMed
    Score: 0.185
  6. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. Int J Chron Obstruct Pulmon Dis. 2021; 16:1925-1938.
    View in: PubMed
    Score: 0.182
  7. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest. 2021 03; 159(3):985-995.
    View in: PubMed
    Score: 0.173
  8. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1430-1436.
    View in: PubMed
    Score: 0.156
  9. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:117-127.
    View in: PubMed
    Score: 0.153
  10. Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. Expert Opin Emerg Drugs. 2017 09; 22(3):285-299.
    View in: PubMed
    Score: 0.140
  11. Safety of inhaled long-acting anti-muscarinic agents in COPD. Postgrad Med. 2017 Jun; 129(5):500-512.
    View in: PubMed
    Score: 0.136
  12. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
    View in: PubMed
    Score: 0.135
  13. Role of anticholinergics in asthma management: recent evidence and future needs. Curr Opin Pulm Med. 2015 Jan; 21(1):103-8.
    View in: PubMed
    Score: 0.116
  14. The efficacy and safety of the novel long-acting ?2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012 Jul; 142(1):119-127.
    View in: PubMed
    Score: 0.098
  15. Bronchodilator reversibility in COPD. Chest. 2011 Oct; 140(4):1055-1063.
    View in: PubMed
    Score: 0.093
  16. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
    View in: PubMed
    Score: 0.090
  17. Budesonide/formoterol combination in COPD: a US perspective. Int J Chron Obstruct Pulmon Dis. 2010 Oct 05; 5:357-66.
    View in: PubMed
    Score: 0.087
  18. The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb; 7(1):17-31.
    View in: PubMed
    Score: 0.083
  19. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther. 2008; 21(3):540-50.
    View in: PubMed
    Score: 0.072
  20. The challenge of differentiating asthma from chronic obstructive pulmonary disease. Manag Care. 2005 Jul; 14(7 Suppl Obstructie Lung):9-15; discussion 24-6.
    View in: PubMed
    Score: 0.060
  21. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther. 2005; 18(1):19-22.
    View in: PubMed
    Score: 0.058
  22. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
    View in: PubMed
    Score: 0.056
  23. Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. Lung. 2024 04; 202(2):119-125.
    View in: PubMed
    Score: 0.055
  24. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023 08; 62(2).
    View in: PubMed
    Score: 0.053
  25. Clinic vs?Home Spirometry for Monitoring Lung Function in Patients With Asthma. Chest. 2023 11; 164(5):1087-1096.
    View in: PubMed
    Score: 0.052
  26. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022 12; 205:107040.
    View in: PubMed
    Score: 0.050
  27. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.
    View in: PubMed
    Score: 0.044
  28. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021 01; 9(1):69-84.
    View in: PubMed
    Score: 0.043
  29. Acute respiratory distress syndrome. Inhaled nitric oxide. Respir Care Clin N Am. 1998 Dec; 4(4):695-709.
    View in: PubMed
    Score: 0.038
  30. Vasodilators in mechanical ventilation. Crit Care Clin. 1998 Oct; 14(4):611-27.
    View in: PubMed
    Score: 0.038
  31. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. Int J Chron Obstruct Pulmon Dis. 2018; 13:2805-2819.
    View in: PubMed
    Score: 0.038
  32. Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic asthmatic patients. Chest. 1998 Sep; 114(3):752-6.
    View in: PubMed
    Score: 0.037
  33. Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):633-643.e1.
    View in: PubMed
    Score: 0.035
  34. Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. J Aerosol Med Pulm Drug Deliv. 2017 Aug; 30(4):256-266.
    View in: PubMed
    Score: 0.034
  35. Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 06; 115:7-12.
    View in: PubMed
    Score: 0.032
  36. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995 Nov; 96(5 Pt 1):571-9.
    View in: PubMed
    Score: 0.031
  37. Adverse effects of inhaled corticosteroids. Am J Med. 1995 Feb; 98(2):196-208.
    View in: PubMed
    Score: 0.029
  38. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan; 12(1):27-34.
    View in: PubMed
    Score: 0.029
  39. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
    View in: PubMed
    Score: 0.029
  40. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
    View in: PubMed
    Score: 0.026
  41. Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med. 2010 Apr; 4(2):155-62.
    View in: PubMed
    Score: 0.021
  42. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008 Aug; 2(4):199-208.
    View in: PubMed
    Score: 0.019
  43. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb; 5(1):25-34.
    View in: PubMed
    Score: 0.018
  44. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
    View in: PubMed
    Score: 0.017
  45. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med. 2006 May; 24(3):259-67.
    View in: PubMed
    Score: 0.016
  46. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther. 2005 May; 27(5):531-42.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.